Literature DB >> 33651309

MiR-23a Is Involved in Myocardial Ischemia/Reperfusion Injury by Directly Targeting CX43 and Regulating Mitophagy.

Lina Wang1, Qing Li1, Jiayu Diao1, Lin Lin1, Jin Wei2.   

Abstract

Activation of CX43 signaling protects myocardial cells from myocardial ischemia/reperfusion (I/R) injury. However, the underlying mechanism remains unclear. MicroRNAs (miRNAs) are well known to play important roles in the progression of diverse diseases. Here, we first confirmed the expression profile of CX43 in rat heart tissues with I/R injury. Then, microRNAs (miRNAs) that target CX43 were predicted using miRDB, miRWalk, and TargetScan. The candidate miR-23a was selected, and its expression level in I/R samples was investigated. To determine the role of miR-23a, rat primary myocardial cells were transfected with miR-23a mimics after they were subjected to hypoxia-reoxygenation (H/R) injury. Transfection of miR-23a mimics stimulated mitophagy through the PINK1/Parkin pathway and downregulated the protein level of CX43. Treatment of miR-23a-transfected cells with NF-kB inhibitors completely abolished miR-23a-mediated mitophagy after H/R. Moreover, miR-23a transfection significantly suppressed CX43 expression and enhanced mitophagy in the model heart in vivo. Therefore, miR-23a plays a detrimental role in myocardial I/R injury by enhancing mitophagy and inhibiting CX43 mRNA.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  acute myocardial infarction; ischemia/reperfusion; miR-23a; mitophagy; transfection CX43

Mesh:

Substances:

Year:  2021        PMID: 33651309     DOI: 10.1007/s10753-021-01443-w

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  37 in total

Review 1.  Critical Issues for the Translation of Cardioprotection.

Authors:  Gerd Heusch
Journal:  Circ Res       Date:  2017-04-28       Impact factor: 17.367

Review 2.  Evolving therapies for myocardial ischemia/reperfusion injury.

Authors:  Borja Ibáñez; Gerd Heusch; Michel Ovize; Frans Van de Werf
Journal:  J Am Coll Cardiol       Date:  2015-04-14       Impact factor: 24.094

3.  Cardioprotection research must leave its comfort zone.

Authors:  Gerd Heusch
Journal:  Eur Heart J       Date:  2018-09-21       Impact factor: 29.983

Review 4.  Connexin-based gap junction hemichannels: gating mechanisms.

Authors:  Juan C Sáez; Mauricio A Retamal; Daniel Basilio; Feliksas F Bukauskas; Michael V L Bennett
Journal:  Biochim Biophys Acta       Date:  2005-03-02

5.  Gap junctional remodeling by hypoxia in cultured neonatal rat ventricular myocytes.

Authors:  Naama Zeevi-Levin; Yaron D Barac; Yotam Reisner; Irina Reiter; Gal Yaniv; Gideon Meiry; Zaid Abassi; Sawa Kostin; Jutta Schaper; Michael R Rosen; Nitzan Resnick; Ofer Binah
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

6.  N-cadherin signals through Rac1 determine the localization of connexin 43 in cardiac myocytes.

Authors:  Takahisa Matsuda; Yasushi Fujio; Tetsurou Nariai; Takashi Ito; Masako Yamane; Tomoka Takatani; Kyoko Takahashi; Junichi Azuma
Journal:  J Mol Cell Cardiol       Date:  2006-03-02       Impact factor: 5.000

Review 7.  Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion.

Authors:  David García-Dorado; Antonio Rodríguez-Sinovas; Marisol Ruiz-Meana
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

8.  The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.

Authors:  Marcus Hortmann; Samuel Robinson; Moritz Mohr; Maximillian Mauler; Daniela Stallmann; Jochen Reinöhl; Daniel Duerschmied; Karlheinz Peter; James Carr; C Michael Gibson; Christoph Bode; Ingo Ahrens
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2017-05-23

9.  Mitochondrial connexin 43 impacts on respiratory complex I activity and mitochondrial oxygen consumption.

Authors:  Kerstin Boengler; Marisol Ruiz-Meana; Sabine Gent; Elvira Ungefug; Daniel Soetkamp; Elisabet Miro-Casas; Alberto Cabestrero; Celia Fernandez-Sanz; Martina Semenzato; Fabio Di Lisa; Susanne Rohrbach; David Garcia-Dorado; Gerd Heusch; Rainer Schulz
Journal:  J Cell Mol Med       Date:  2012-08       Impact factor: 5.310

Review 10.  Ischaemic conditioning and reperfusion injury.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

View more
  6 in total

Review 1.  Hypoxic/Ischemic Inflammation, MicroRNAs and δ-Opioid Receptors: Hypoxia/Ischemia-Sensitive Versus-Insensitive Organs.

Authors:  Yimeng Chen; Yichen He; Shuchen Zhao; Xiaozhou He; Dong Xue; Ying Xia
Journal:  Front Aging Neurosci       Date:  2022-05-09       Impact factor: 5.702

Review 2.  Multilayer control of cardiac electrophysiology by microRNAs.

Authors:  Dandan Yang; Isabelle Deschênes; Ji-Dong Fu
Journal:  J Mol Cell Cardiol       Date:  2022-03-03       Impact factor: 5.763

3.  The protective effect of pericytes on vascular permeability after hemorrhagic shock and their relationship with Cx43.

Authors:  Shuangshuang He; Zisen Zhang; Xiaoyong Peng; Yue Wu; Yu Zhu; Li Wang; Henan Zhou; Tao Li; Liangming Liu
Journal:  Front Physiol       Date:  2022-10-03       Impact factor: 4.755

Review 4.  Mitophagy Regulation Following Myocardial Infarction.

Authors:  Annie Turkieh; Yara El Masri; Florence Pinet; Emilie Dubois-Deruy
Journal:  Cells       Date:  2022-01-07       Impact factor: 6.600

Review 5.  Impact of the Main Cardiovascular Risk Factors on Plasma Extracellular Vesicles and Their Influence on the Heart's Vulnerability to Ischemia-Reperfusion Injury.

Authors:  Miłosz Majka; Marcin Kleibert; Małgorzata Wojciechowska
Journal:  Cells       Date:  2021-11-27       Impact factor: 6.600

Review 6.  The Regulation Mechanisms and Clinical Application of MicroRNAs in Myocardial Infarction: A Review of the Recent 5 Years.

Authors:  Chan Wu; Binghong Liu; Ruiying Wang; Gang Li
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.